Stay updated with breaking news from Anteris bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ The "Site Management Organizations Market by Therapeutic Areas, Trial Phases, Clinical Trial Components, Type of Interventions and Key. ....
5 Penny Stocks To Watch This Week With the approval of a new vaccine and a bullish response from investors, penny stocks are showing higher volume across the board. While heightened volume may not seem like a big deal, it indicates several factors about individual security. For one, higher than average volume means more investor attention. Simply, the higher the volume, the more shares are trading hands between investors. We see volume trends across either individual companies or entire industries. This can be indicative of either announcements specific to a company or larger implications for a broader industry as a whole. ....
by Barry Teater, NCBiotech writer December 16, 2020 . RESEARCH TRIANGLE PARK – vTv Therapeutics of High Point has out-licensed worldwide development and commercialization rights to its potential kidney disease drug to a California biotech company in a deal that ultimately could be worth more than $150 million. Under the terms of the agreement, Anteris Bio will pay vTv $2 million up front and up to $151 million for future development, regulatory and commercial sales milestones, as well as royalties on annual net sales. In addition, vTv will receive a minority equity stake in Anteris. Anteris is a newly formed portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 in Oakland, Calif., by former Novartis CEO Joe Jimenez and Mark Fishman, M.D., former president of the Novartis Institutes for BioMedical Research. ....
Aditum Bio launches third company, Anteris Bio, in collaboration with TrialSpark - Aditum Bio spin-out companies such as Anteris Bio will leverage TrialSpark s clinical development engine to rapidly advance their drug assets through clinical trials. News provided by Share this article Share this article NEW YORK, Dec. 16, 2020 /PRNewswire/ TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, formally announces a collaboration with Aditum Bio, a San Francisco-based venture firm focused on acquiring and developing biotechnology assets that will benefit patients. Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio s drug development partner, TrialSpark will support Anteris Bio using its innovative, tech-enabled clinical development model. ....
Share: Eli Lilly (NYSE: LLY) shares are trading higher on Tuesday after the company announced it will acquire Prevail for total consideration of $26.50 per share in cash. The company also issued the fiscal year 2020 EPS and sales guidance above analyst estimates. Eli Lilly shares were trading up 3.01% to $162.64 at the time of publication on Tuesday. The stock has a 52-week high of $170.75 and a 52-week low of $117.06. BioNTech s (NASDAQ: BNTX) shares are trading higher following reports suggesting the European Medicines Agency is aiming to approve the company s COVID-19 vaccine on Dec. 23. BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab and does not yet have any commercialized medicines. ....